Paid Clinical Trials - 82,000 Members & Growing

  • Paid Clinical Trials
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.

Sponsored Links







  • Condition:   Severe Hemophilia A
    Intervention:   Drug: Long-acting recombinant factor VIII Fc fusion protein
    Sponsor:   University of Pittsburgh
    Not yet recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Selinexor;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Dexamethasone
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Karyopharm Therapeutics, Inc
    Not yet recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MV-NIS
    Sponsor:   University of Arkansas
    Not yet recruiting - verified July 2014

  • Condition:   Waldenström Macroglobulinemia (WM)
    Intervention:   Drug: ACP-196
    Sponsor:   Acerta Pharma BV
    Not yet recruiting - verified July 2014

  • Conditions:   Heart Failure;   Multiple Myeloma
    Intervention:  
    Sponsors:   Vanderbilt University;   Daniel Lenihan;   Millennium Pharmaceuticals, Inc.
    Not yet recruiting - verified June 2014

  • Conditions:   Multiple Myeloma in Relapse;   Multiple Myeloma, Refractory
    Interventions:   Drug: Pomalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Mount Sinai School of Medicine;   Ajai Chari;   Celgene Corporation
    Recruiting - verified June 2014

  • Conditions:   Acute Leukemia;   Chronic Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Multiple Myeloma
    Intervention:   Drug: MLN9708
    Sponsors:   Northside Hospital, Inc.;   Millennium Pharmaceuticals, Inc.
    Not yet recruiting - verified June 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: bendamustine hydrochloride;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   Comprehensive Cancer Center of Wake Forest University;   National Cancer Institute (NCI)
    Not yet recruiting - verified June 2014

  • Condition:   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
    Sponsors:   Pharmacyclics;   Janssen Research & Development, LLC
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ACY-1215 in combination with pomalidomide and dexamethasone
    Sponsor:   Acetylon Pharmaceuticals Incorporated
    Not yet recruiting - verified July 2014

  • Conditions:   Multiple Myeloma;   Bone Marrow Failure Syndromes;   Hemoglobinopathies;   AML;   ALL;   Myeloid Leukemia, Chronic;   NHL;   HL;   MDS;   Amyloidosis;   Myelofibrosis
    Interventions:   Drug: Tacrolimus;   Drug: Anti-thymocyte globulin;   Procedure: Kidney transplant;   Drug: Bone marrow transplant from a related donor;   Radiation: Total body irradiation 400 centigray (200 cGy X 2)
    Sponsor:   Massachusetts General Hospital
    Not yet recruiting - verified June 2014

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: CPI-0610
    Sponsors:   Constellation Pharmaceuticals;   The Leukemia and Lymphoma Society
    Not yet recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Cohort 1: Carfilzomib 15 mg/m2;   Drug: Cohort 2: Carfilzomib 20 mg/m2;   Drug: Cohort 3: Carfilzomib 27 mg/m2
    Sponsor:   Spectrum Health Hospitals
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Trametinib
    Sponsor:   University of Arkansas
    Not yet recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:   Biological: CART-19 T cells
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified May 2014

  • Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: azacitidine;   Drug: Sonidegib;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Relapsed and Refractory Multiple Myeloma
    Interventions:   Drug: LGH447;   Drug: BYL719
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Not yet recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: VELCADE (Bortezomib);   Drug: Dexamethasone
    Sponsor:   Janssen Research & Development, LLC
    Not yet recruiting - verified July 2014

  • Conditions:   Acute Myeloid Leukemia;   Hematologic Malignancies;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma,;   Multiple Myeloma;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis;   Myeloproliferative Syndrome
    Interventions:   Radiation: total marrow irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: myeloid progenitor cell transplantation;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Other: Psychoeducational intervention;   Behavioral: behavioral intervention;   Other: counseling intervention;   Other: educational intervention;   Other: telephone-based intervention;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Chronic HCV Infection
    Interventions:   Drug: LDV/SOF;   Drug: Sofosbuvir;   Drug: Ribavirin
    Sponsor:   Gilead Sciences
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: MEL-CFZ-TD-PACE
    Sponsors:   University of Arkansas;   Onyx Pharmaceuticals
    Recruiting - verified June 2014

  • Conditions:   Thrombocytosis;   Myeloproliferative Neoplasms
    Intervention:   Drug: Anagrelide CR
    Sponsor:   Galena Biopharma, Inc.
    Recruiting - verified July 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: ixazomib;   Drug: dexamethasone;   Drug: pomalidomide;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Myelogenous, Chronic;   Multiple Myeloma
    Interventions:   Radiation: Dynamic contrast-enhanced computed tomography;   Drug: Ioversol
    Sponsor:   Washington University School of Medicine
    Recruiting - verified June 2014

  • Conditions:   Congenital Bleeding Disorder;   Haemophilia B
    Intervention:   Drug: nonacog beta pegol
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified July 2014

  • Conditions:   Congenital Bleeding Disorder;   Haemophilia A
    Intervention:   Drug: turoctocog alfa pegol
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Vermurafenib
    Sponsor:   University of Arkansas
    Not yet recruiting - verified April 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   HIV Infection;   Intraocular Lymphoma;   Multicentric Castleman Disease;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: ibrutinib;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified April 2014

  • Conditions:   Solid Tumors;   Multiple Myeloma;   Non-Hodgkins Lymphoma
    Intervention:   Drug: DCR-MYC
    Sponsor:   Dicerna Pharmaceuticals, Inc.
    Recruiting - verified April 2014

  • Condition:   ATIII Deficiency
    Interventions:   Drug: Anti-thrombin III;   Other: Placebo
    Sponsors:   Duke University;   Grifols Biologicals Inc.
    Not yet recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Granix;   Drug: High dose melphalan (HDR);   Procedure: Autologous Stem Cell Transplant (ASCT)
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified June 2014

  • Conditions:   Primary Myelofibrosis (PMF),;   Post-polycythemia Vera (Post-PV);   Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
    Interventions:   Drug: Momelotinib;   Drug: Best Available Therapy (BAT)
    Sponsor:   Gilead Sciences
    Recruiting - verified July 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Biological: wild-type reovirus;   Drug: carfilzomib;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Not yet recruiting - verified June 2014

  • Conditions:   Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
    Interventions:   Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
    Sponsors:   Triphase Research and Development I Corporation;   Celgene Corporation
    Recruiting - verified June 2014

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease
    Intervention:   Drug: TG-0054 combined with G-CSF
    Sponsor:   TaiGen Biotechnology Co., Ltd.
    Not yet recruiting - verified April 2014

  • Condition:   Leukemia
    Interventions:   Drug: LCL-161;   Behavioral: Questionnaires;   Other: Phone Calls
    Sponsors:   M.D. Anderson Cancer Center;   Novartis
    Not yet recruiting - verified May 2014

  • Conditions:   End Stage Renal Failure on Dialysis;   Complication of Dialysis;   Blood Coagulation Disorders
    Intervention:  
    Sponsors:   Mayo Clinic;   Marie Hogan;   Medisystems Corporation
    Recruiting - verified March 2014

  • Condition:   Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   Onyx Therapeutics, Inc.
    Recruiting - verified April 2014

  • Conditions:   Multiple Myeloma;   Lymphoma, Non-Hodgkin
    Interventions:   Drug: XM02 Filgrastim;   Drug: Filgrastim;   Procedure: Apheresis;   Drug: Plerixafor
    Sponsor:   Washington University School of Medicine
    Not yet recruiting - verified June 2014

  • Condition:   Advanced Multiple Myeloma
    Interventions:   Drug: Filanesib, KSP (Eg5) inhibitor; intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
    Sponsor:   Array BioPharma
    Recruiting - verified July 2014

  • Condition:   Waldenstrom's Macroglobulinemia
    Interventions:   Drug: IMO-8400;   Drug: IMO-8400;   Drug: IMO-8400
    Sponsor:   Idera Pharmaceuticals, Inc.
    Recruiting - verified June 2014

  • Conditions:   Blood Coagulation Disorders;   Trauma;   Acute Coagulopathy
    Intervention:   Other: Blood collection
    Sponsor:   University of Rochester
    Recruiting - verified March 2014

  • Conditions:   Multiple Myeloma;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma
    Intervention:   Device: Administration of hyperbaric oxygen
    Sponsors:   University of Kansas;   Southwest Oncology Group
    Recruiting - verified April 2014

  • Condition:   Severe Hemophilia A
    Intervention:   Biological: BIIB031 (rFVIIIFc)
    Sponsor:   Biogen Idec
    Recruiting - verified July 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: erismodegib;   Drug: lenalidomide
    Sponsor:   Mayo Clinic
    Recruiting - verified March 2014

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2014

  • Condition:   Immune Thrombocytopenic Purpura
    Interventions:   Drug: Fostamatinib Disodium;   Drug: Placebo
    Sponsor:   Rigel Pharmaceuticals
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Yvonne Efebera;   CureTech Ltd
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified July 2014

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: nab-paclitaxel
    Sponsors:   New York University School of Medicine;   Celgene Corporation
    Recruiting - verified June 2014

  • Conditions:   Adult Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma Recurrent;   Lymphoma, Follicular;   Marginal Zone B-Cell Lymphoma;   Malignant Lymphoma - Lymphoplasmacytic;   Waldenstrom Macroglobulinemia;   Small Lymphocytic Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   T-Cell Lymphoma
    Intervention:   Drug: Doxycycline
    Sponsor:   University of Rochester
    Recruiting - verified May 2014

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Intervention:   Biological: ALT-803
    Sponsors:   Altor Bioscience Corporation;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2014

  • Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Meloxicam;   Drug: Filgrastim
    Sponsors:   Indiana University;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Heart Failure;   Respiratory Insufficiency;   Stroke Acute;   Infectious Diseases;   Rheumatic Diseases
    Interventions:   Drug: Rivaroxaban, 10 mg;   Drug: Rivaroxaban, 7.5 mg;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified July 2014

  • Condition:   Wiskott-Aldrich Syndrome
    Intervention:  
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Primary Immune Deficiency Treatment Consortium (PIDTC);   Rare Diseases Clinical Research Network (RDCRN)
    Recruiting - verified June 2014

  • Conditions:   Non-Hodgkin's Lymphoma (NHL);   Multiple Myeloma;   Waldenstrom's Macroglobulinemia (WM);   Diffuse Large B-cell Lymphoma (DLBCL),;   Other B-cell NHL Subtypes, Including WM;   T-cell NHL
    Intervention:   Drug: CB-839
    Sponsor:   Calithera Biosciences, Inc
    Recruiting - verified June 2014

  • Condition:   Native Arteriovenous Fistula
    Interventions:   Drug: Topical Tranexamic Acid;   Drug: Topical Bacitracin
    Sponsors:   California Institute of Renal Research;   Imprimis Pharmaceuticals, Inc.
    Not yet recruiting - verified April 2014

  • Conditions:   Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
    Interventions:   Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting - verified May 2014

  • Conditions:   Primary Myelofibrosis;   Post-polycythemia Vera Myelofibrosis;   Post-essential Thrombocythemia Myelofibrosis
    Interventions:   Drug: Pacritinib;   Drug: Best Available Therapy
    Sponsor:   CTI BioPharma
    Recruiting - verified July 2014

  • Condition:   Hemophilia B
    Intervention:   Biological: rIX-FP
    Sponsor:   CSL Behring
    Recruiting - verified June 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: PI3K inhibitor BKM120;   Biological: rituximab;   Other: Pharmacodynamics;   Other: Correlative studies
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Kami Maddocks;   Novartis
    Not yet recruiting - verified May 2014

  • Conditions:   Solid Tumors;   Multiple Myeloma
    Intervention:   Drug: TAS-120
    Sponsor:   Taiho Oncology, Inc.
    Not yet recruiting - verified January 2014

  • Conditions:   Multiple Myeloma, Relapsed;   Multiple Myeloma, Refractory to Standard Treatment
    Interventions:   Radiation: Total Marrow Irradiation;   Drug: Melphalan;   Drug: Filgrastim (G-CSF)
    Sponsor:   University of Illinois at Chicago
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Interventions:   Radiation: Total Marrow Irradiation;   Procedure: Autologous Transplant;   Drug: Melphalan;   Drug: Filgrastim (G-CSF)
    Sponsor:   University of Illinois at Chicago
    Recruiting - verified June 2014

  • Condition:   Idiopathic Thrombocytopenia Purpura
    Intervention:  
    Sponsor:   Weill Medical College of Cornell University
    Recruiting - verified January 2014

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Pembrolizumab;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   Merck Sharp & Dohme Corp.;   Celgene Corporation
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsor:   University of Arkansas
    Recruiting - verified January 2014

  • Condition:   Hemophilia A
    Interventions:   Biological: GreenGene™ F;   Biological: GreenGene™ F
    Sponsors:   Green Cross Corporation;   Atlantic Research Group
    Recruiting - verified January 2014

  • Conditions:   Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
    Intervention:   Biological: Coagulation Factor VIIa (Recombinant)
    Sponsors:   rEVO Biologics;   Laboratoire français de Fractionnement et de Biotechnologies
    Recruiting - verified April 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
    Sponsors:   Indiana University;   Indiana University School of Medicine;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Palbociclib;   Drug: Dexamethasone;   Drug: Lenalidomide
    Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation;   Pfizer
    Not yet recruiting - verified January 2014

  • Conditions:   Myeloma, Multiple;   Paraproteinemias;   Hematologic Neoplasms
    Intervention:  
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting - verified May 2014

  • Condition:   Purpura, Thrombocytopenic, Idiopathic
    Intervention:   Drug: BI 655064
    Sponsor:   Boehringer Ingelheim
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bendamustine;   Drug: Carfilzomib;   Drug: Dexamethasone
    Sponsors:   Columbia University;   Suzanne Lentzsch, MD
    Recruiting - verified December 2013

  • Conditions:   Polycythemia Vera;   Essential Thrombocythemia
    Intervention:   Drug: Momelotinib
    Sponsor:   Gilead Sciences
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Oprozomib;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Velcade;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Thalidomide;   Drug: Diphenhydramine;   Drug: Acetaminophen
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified June 2014

  • Condition:   Severe Hemophilia A
    Intervention:   Biological: Human-cl rhFVIII
    Sponsor:   Octapharma
    Recruiting - verified May 2014

  • Condition:   Hemophilia B
    Intervention:   Biological: IB1001
    Sponsor:   Cangene Corporation
    Not yet recruiting - verified January 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ACY-1215 in combination with pomalidomide and dexamethasone
    Sponsor:   Acetylon Pharmaceuticals Incorporated
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Biological: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs);   Other: Standard of care
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Rockefeller University
    Recruiting - verified June 2014

  • Condition:   Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: All-Trans Retinoic Acid (ATRA)
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified June 2014

  • Condition:   Postoperative Ecchymosis
    Intervention:   Drug: DDAVP
    Sponsor:   University Hospitals of Cleveland
    Not yet recruiting - verified November 2013

  • Condition:   Advanced Multiple Myeloma
    Interventions:   Drug: Carfilzomib, proteasome inhibitor; intravenous;   Drug: Filanesib, KSP(Eg5) inhibitor; intravenous;   Drug: Dexamethasone, steroid; oral or intravenous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
    Sponsor:   Array BioPharma
    Recruiting - verified July 2014

  • Conditions:   Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
    Interventions:   Biological: PRM-151;   Drug: Ruxolitinib
    Sponsor:   Promedior, Inc.
    Recruiting - verified January 2014

  • Condition:   Postpartum Hemorrhage
    Intervention:   Drug: Tranexamic Acid
    Sponsor:   Brigham and Women's Hospital
    Not yet recruiting - verified December 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Romidepsin;   Drug: pomalidomide;   Drug: Dexamethasone
    Sponsors:   Weill Medical College of Cornell University;   Celgene Corporation
    Recruiting - verified November 2013

  • Conditions:   Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
    Interventions:   Drug: Momelotinib;   Drug: Ruxolitinib;   Drug: Placebo to match momelotinib;   Drug: Placebo to match ruxolitinib
    Sponsor:   Gilead Sciences
    Recruiting - verified July 2014

  • Condition:   Immune Thrombocytopenia
    Intervention:   Drug: Second Line ITP agents
    Sponsors:   Children's Hospital Boston;   Terrana ITP Research Fund
    Recruiting - verified October 2013

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Fenofibrate
    Sponsor:   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma in Relapse
    Interventions:   Drug: Panobinostat;   Drug: Dexamethasone;   Drug: Lenalidomide;   Drug: Bortezomib
    Sponsors:   Dana-Farber Cancer Institute;   Novartis
    Recruiting - verified May 2014

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Multiple Myeloma;   Hematopoietic Stem Cells
    Interventions:   Drug: GCSF;   Drug: meloxicam;   Drug: Placebo
    Sponsors:   Massachusetts General Hospital;   The Leukemia and Lymphoma Society
    Not yet recruiting - verified December 2013

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified May 2014

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: busulfan;   Drug: etoposide;   Drug: cyclophosphamide;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   a Diagnosis of MGUS or SMM by IMWG Criteria
    Intervention:  
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified October 2013

  • Conditions:   ADA-SCID;   Adenosine Deaminase Deficiency;   Wiskott- Aldrich Syndrome;   Primary Immunodeficiencies;   Severe Combined Immune Deficiency
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI);   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Placebo;   Drug: Dexamethasone
    Sponsors:   Pharmacyclics;   Janssen Research & Development, LLC;   Onyx Therapeutics, Inc.
    Recruiting - verified May 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: SMAC mimetic LCL161;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: quality-of-life assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: ibrutinib;   Drug: lenalidomide;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: bortezomib;   Drug: lenalidomide;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
    Intervention:   Biological: Pembrolizumab
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting - verified July 2014

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Monoclonal Gammopathy of Undetermined Significance;   Smoldering Multiple Myeloma
    Intervention:   Behavioral: Relaxation Response Resiliency Program (3RP)
    Sponsors:   Massachusetts General Hospital;   Dana-Farber Cancer Institute
    Recruiting - verified October 2013

  • Condition:   Hemophilia A
    Intervention:   Biological: PEGylated Recombinant Factor VIII
    Sponsor:   Baxter Healthcare Corporation
    Recruiting - verified October 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsor:   Celgene Corporation
    Recruiting - verified May 2014

  • Condition:   Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: G-CSF;   Behavioral: Phone Calls
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified June 2014

  • Conditions:   Lymphoid Malignancies;   Multiple Myeloma;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
    Interventions:   Drug: Pralatrexate;   Drug: Romidepsin
    Sponsors:   Columbia University;   Jennifer Amengual;   Northwestern University
    Recruiting - verified April 2014

  • Conditions:   Relapsed Multiple Myeloma;   End-stage Renal Disease
    Intervention:   Drug: Carfilzomib
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified June 2014

  • Condition:   Thrombotic Thrombocytopenic Purpura
    Intervention:   Biological: Octaplas
    Sponsor:   Octapharma
    Not yet recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone
    Sponsors:   Emory University;   Onyx Therapeutics, Inc.
    Recruiting - verified May 2014

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: bortezomib;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Single Umbilical Cord Blood Transplantation;   Non-myeloablative Conditioning;   Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Marginal Zone Lymphoma;   Follicular Lymphomas;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Mantle-cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Prolymphocytic Leukemia
    Intervention:   Drug: HSC835
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Not yet recruiting - verified June 2014

  • Conditions:   Polycythemia Vera;   Essential Thrombocythemia
    Intervention:   Procedure: Blood specimen
    Sponsors:   Mount Sinai School of Medicine;   The Leukemia and Lymphoma Society
    Recruiting - verified June 2014

  • Condition:   Myeloma
    Interventions:   Drug: Thalidomide;   Drug: Lenalidomide;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified March 2014

  • Condition:   Ecchymosis and Erythema Commonly Associated With Soft Tissue Filler Injections and Facial Ablative Laser Resurfacing Treatments.
    Intervention:   Dietary Supplement: Multizyme Cellular Vitality Cyruta Plus SHEP
    Sponsors:   DeNova Research;   Standard Process Inc.
    Recruiting - verified August 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: peripheral blood stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Coagulopathy;   Mesothelioma
    Intervention:   Procedure: Blood draw for TEG analysis
    Sponsor:   Brigham and Women's Hospital
    Not yet recruiting - verified July 2013

  • Condition:   Multiple Myeloma (MM)
    Interventions:   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Lenalidomide
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2014

  • Conditions:   Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman Diamond Syndrome;   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Chediak Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia;   Hemophagocytic Lymphohistiocytosis
    Interventions:   Drug: 4 doses of abatacept;   Drug: 6 doses of abatacept
    Sponsor:   Emory University
    Recruiting - verified March 2014

  • Conditions:   Coagulopathy;   Nosocomial Pneumonia
    Interventions:   Dietary Supplement: Vitamin C;   Dietary Supplement: Vitamin E;   Dietary Supplement: Saline (for Vitamin C);   Drug: Placebo (for Vitamin E)
    Sponsor:   University of Alabama at Birmingham
    Recruiting - verified January 2014

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Drug: carfilzomib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Onyx Pharmaceuticals
    Recruiting - verified April 2014

  • Condition:   Cancer of Kidney
    Intervention:   Device: Microwave pre-coagulation
    Sponsor:   University of Wisconsin, Madison
    Not yet recruiting - verified August 2013

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: desipramine hydrochloride;   Biological: filgrastim;   Other: laboratory biomarker analysis
    Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   National Cancer Institute (NCI);   Montefiore Medical Center
    Recruiting - verified May 2014

  • Condition:   Relapsed and/or Relapsed-refractory Multiple Myeloma
    Interventions:   Drug: Melflufen;   Drug: Dexamethasone
    Sponsor:   Oncopeptides AB
    Recruiting - verified January 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: alisertib;   Drug: romidepsin;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Hemophilia A
    Intervention:   Biological: PEGylated Recombinant factor VIII (rFVIII)
    Sponsors:   Baxter Healthcare Corporation;   Baxter Innovations GmbH
    Recruiting - verified January 2014

  • Condition:   Newly Diagnosed, Previously Untreated Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Biological: Elotuzumab
    Sponsors:   Bristol-Myers Squibb;   Abbott
    Recruiting - verified January 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Treatment with NY-ESO-1c259-modified T cells
    Sponsor:   Adaptimmune
    Recruiting - verified November 2013

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Germ Cell Neoplasms;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Immunodeficiency Diseases
    Intervention:  
    Sponsor:   Comprehensive Cancer Center of Wake Forest University
    Recruiting - verified January 2014

  • Condition:   Multiple Myeloma in Relapse
    Intervention:   Drug: Combination pomalidomide, everolimus and dexamethasone
    Sponsors:   New Mexico Cancer Care Alliance;   Novartis Corporation
    Not yet recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Oprozomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified June 2014

  • Conditions:   Acute Myelogenous Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndromes (MDS);   Lymphoma;   Myeloma;   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML)
    Intervention:   Biological: ALT-803
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Condition:   Asymptomatic Multiple Myeloma
    Intervention:   Drug: ENK Cell Infusion
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified July 2014

  • Conditions:   Leukemia;   Myeloma;   Myeloproliferative Diseases
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Alemtuzumab;   Procedure: Stem Cell infusion;   Drug: Tacrolimus;   Drug: Mini Methotrexate;   Drug: G-CSF;   Procedure: Donor Lymphocyte Infusion (DLI);   Drug: AP1903;   Drug: Methylprednisolone;   Behavioral: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   Bellicum Pharmaceuticals
    Recruiting - verified May 2014

  • Condition:   Relapsed or Refractory Multiple Myeloma
    Intervention:   Drug: Cabozantinib (XL184)
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Exelixis
    Recruiting - verified May 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: anti-CD19-CAR lentiviral vector-transduced autologous T lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: ixazomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Myeloma
    Intervention:   Drug: Lenalidomide, Dexamethasone, and MEDI-551
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   MedImmune LLC
    Recruiting - verified June 2014

  • Conditions:   Heart Failure;   Respiratory Failure
    Intervention:  
    Sponsors:   University of California, San Francisco;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Biological: aMIL;   Drug: No aMIL
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   The Leukemia and Lymphoma Society
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Intervention:   Biological: PCV13
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting - verified May 2014

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Conditions:   Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
    Sponsors:   University of Iowa;   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Conditions:   Tumor;   Cancer;   Pain;   Malignant Solid Tumor;   Unresectable Malignant Neoplasm;   Hematologic Malignancy;   Multiple Myeloma;   Lymphoma;   Neoplasm Metastasis
    Intervention:   Drug: Sodium Bicarbonate
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Reliable Cancer Therapies
    Recruiting - verified July 2014

  • Conditions:   Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
    Intervention:   Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
    Sponsor:   University of Pittsburgh
    Recruiting - verified August 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: IXAZOMIB + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified July 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified April 2014

  • Conditions:   Trauma;   Hemorrhagic Shock
    Interventions:   Biological: Type AB plasma;   Drug: Crystalloid fluid (standard of care for resuscitation)
    Sponsors:   Denver Health and Hospital Authority;   U.S. Army Medical Research and Materiel Command;   University of Colorado, Denver
    Not yet recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Oprozomib;   Drug: Dexamethasone
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified July 2014

  • Conditions:   Primary Liver Cancer;   Solid Tumors;   Lymphoma;   AML;   ALL;   CLL;   CML in Accelerated or Blast Phase;   Multiple Myeloma;   MDS
    Intervention:   Drug: MRX34
    Sponsors:   Mirna Therapeutics, Inc.;   Cancer Prevention Research Institute of Texas
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: IXAZOMIB;   Drug: dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Biological: WT1 Analog Peptide Vaccine;   Biological: Sargramostim (GM-CSF);   Drug: lenalidomide
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified April 2014

  • Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: ipilimumab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
    Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    Sponsor:   Washington University School of Medicine
    Recruiting - verified April 2014

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Nephrotic Syndrome;   Hyperlipidemia
    Intervention:   Drug: Pravastatin
    Sponsor:   University of North Carolina, Chapel Hill
    Recruiting - verified December 2013

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Acupuncture;   Procedure: Sham acupuncture
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified July 2014

  • Conditions:   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: alisertib;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Kristie Blum;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified November 2013

  • Conditions:   Anxiety Disorder;   Worry;   Uncertainty;   Sleep Disorders;   Insomnia;   Fatigue;   Pain;   Depression;   Cognitive-behavioral Therapy;   Psychological Intervention;   Esophageal Cancer;   Pancreatic Cancer;   Leukemia;   Lung Cancer;   Multiple Myeloma;   Ovarian Neoplasm;   Stage III or IV Cervical or Uterine Cancer;   Stage IIIB, IIIC, or IV Breast Cancer;   Glioblastoma Multiforme;   Relapsed Lymphoma;   Stage III or IV Colorectal Cancer;   Stage IIIC or IV Melanoma
    Intervention:   Behavioral: Cognitive-behavioral therapy for worry, uncertainty & insomnia
    Sponsors:   Ohio State University Comprehensive Cancer Center;   American Cancer Society, Inc.;   Lance Armstrong Foundation
    Recruiting - verified August 2013

  • Conditions:   Relapsed Waldenström's Macroglobulinemia (WM).;   Prior Bortezomib Therapy Acceptable.
    Interventions:   Drug: Carfilzomib;   Drug: Rituximab;   Drug: Dexamethasone
    Sponsors:   Hackensack University Medical Center;   Onyx Therapeutics, Inc.
    Recruiting - verified February 2014

  • Conditions:   Multiple Myeloma;   Disease of the Marrow;   Osteoporosis
    Intervention:  
    Sponsor:   New York University School of Medicine
    Recruiting - verified May 2014

  • Condition:   Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Melphalan;   Drug: Dexamethasone;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified June 2014

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Epstein-Barr Virus Infection;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: brentuximab vedotin;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsors:   Northwestern University;   Seattle Genetics, Inc.
    Recruiting - verified April 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Drug: dexamethasone
    Sponsor:   Mayo Clinic
    Recruiting - verified March 2014

  • Condition:   Myeloma
    Interventions:   Drug: Minocycline;   Other: Placebo;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified June 2014

  • Conditions:   Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
    Intervention:   Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
    Sponsors:   Mount Sinai School of Medicine;   John Mascarenhas;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Incyte Corporation;   Novartis
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified August 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I AIDS-related Lymphoma;   Stage II AIDS-related Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: carmustine;   Drug: cytarabine;   Drug: melphalan;   Drug: etoposide;   Drug: O6-benzylguanine;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting - verified June 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Thomas Jefferson University
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Carfilzomib and Dexamethasone
    Sponsors:   Oncotherapeutics;   Onyx Pharmaceuticals
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: busulfan;   Drug: melphalan;   Drug: fludarabine;   Biological: anti-thymocyte globulin (ATG);   Procedure: a T cell depleted stem cell transplant
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified July 2014

  • Conditions:   Multiple Myeloma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Romidepsin;   Drug: Lenalidomide
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Saint Francis/Mount Sinai Regional Cancer Center;   Weill Medical College of Cornell University;   University of Nebraska;   Celgene Corporation;   Biologics, Inc.
    Recruiting - verified June 2014

  • Conditions:   Chronic Kidney Disease;   Acute Myeloid Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Chronic Myelogenous Leukemia (CML);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkin's Lymphoma (NHL);   Hodgkin Disease;   Multiple Myeloma;   Myelodysplastic Syndrome (MDS);   Aplastic Anemia;   AL Amyloidosis;   Diamond Blackfan Anemia;   Myelofibrosis;   Myeloproliferative Disease;   Sickle Cell Anemia;   Autoimmune Diseases;   Thalassemia
    Intervention:   Procedure: Haploidentical Bone Marrow/Kidney
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified February 2014

  • Condition:   Relapsed/Refractory Multiple Myeloma
    Interventions:   Drug: ABT-199;   Drug: bortezomib;   Drug: dexamethasone
    Sponsors:   AbbVie;   AbbVie (prior sponsor, Abbott);   Genentech
    Recruiting - verified May 2014

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
    Interventions:   Biological: anti-endosialin/TEM1 monoclonal antibody MORAb-004;   Other: pharmacological study;   Other: laboratory biomarker analysis
    Sponsors:   Morphotek;   National Cancer Institute (NCI);   The Children's Oncology Group (COG)
    Recruiting - verified July 2014

  • Conditions:   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Biological: Palifermin;   Biological: Lupron;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Swedish Orphan Biovitrum
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Procedure: stem cell;   Drug: Dexamethasone;   Drug: Clarithromycin
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Celgene Corporation;   Weill Medical College of Cornell University;   North Shore University Hospital;   Rutgers Cancer Institute of New Jersey;   State University of New York - Upstate Medical University
    Recruiting - verified July 2014

  • Conditions:   Multiple Myeloma;   Lymphoma
    Intervention:   Drug: CUDC-907
    Sponsors:   Curis, Inc.;   The Leukemia and Lymphoma Society
    Recruiting - verified August 2013

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsor:   Washington University School of Medicine
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bendamustine;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsors:   Duke University;   Cristina Gasparetto;   Celgene Corporation
    Recruiting - verified January 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsor:   Celgene Corporation
    Recruiting - verified July 2014

  • Conditions:   Anemia;   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: ruxolitinib phosphate;   Drug: danazol;   Other: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: ipilimumab;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Velcade;   Drug: Cyclophosphamide;   Drug: Revlimid
    Sponsors:   Duke University;   Sascha Tuchman, MD;   Millennium Pharmaceuticals, Inc.;   Duke Cancer Institute
    Recruiting - verified July 2014

  • Conditions:   Light Chain Deposition Disease;   Primary Systemic Amyloidosis
    Interventions:   Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Melphalan;   Procedure: NK Cell Infusion;   Drug: Interleukin-2;   Procedure: Stem Cell Infusion;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Celgene Corporation
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Velcade
    Sponsor:   University of Utah
    Recruiting - verified May 2014

  • Condition:   Smoldering Multiple Myeloma
    Intervention:   Biological: PVX-410
    Sponsor:   OncoPep, Inc.
    Recruiting - verified May 2014

  • Condition:   Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: MLN9708;   Radiation: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified July 2014

  • Condition:   Severe Hemophilia A
    Intervention:   Biological: Human cl rhFVIII
    Sponsor:   Octapharma
    Recruiting - verified December 2013

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: dinaciclib;   Drug: bortezomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: DKN-01 300 mg;   Drug: DKN-01 600 mg;   Drug: Standard of Care
    Sponsor:   HealthCare Pharmaceuticals, Inc.
    Recruiting - verified June 2014

  • Condition:   Relapsed/Refractory Multiple Myeloma
    Intervention:   Drug: ABT-199
    Sponsors:   AbbVie;   AbbVie (prior sponsor, Abbott);   Genentech
    Recruiting - verified May 2014

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: brentuximab vedotin;   Other: laboratory biomarker analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: alisertib;   Drug: bortezomib;   Biological: rituximab;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Relapse Multiple Myeloma;   Refractory Multiple Myeloma
    Intervention:   Drug: Carfilzomib
    Sponsors:   Mount Sinai School of Medicine;   Ajai Chari;   Onyx Pharmaceuticals
    Recruiting - verified December 2013

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: hydroxychloroquine;   Drug: sirolimus;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Multiple Sclerosis
    Intervention:  
    Sponsor:   Bastyr University
    Recruiting - verified July 2014

  • Condition:   Hemophilia B
    Intervention:   Biological: AskBio009
    Sponsor:   Asklepios Biopharmaceutical, Inc.
    Recruiting - verified March 2014

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Biological: indium In 111 anti-CD45 monoclonal antibody BC8;   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: carfilzomib
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified June 2014

  • Conditions:   Hodgkin Disease;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Lymphomatoid Granulomatosis;   Leukemia-Lymphoma, Adult T-Cell
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Thrombocytopenia
    Intervention:   Biological: romiplostim
    Sponsors:   New York University School of Medicine;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Subcutaneous bortezomib
    Sponsors:   Oncotherapeutics;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2014

  • Conditions:   Multiple Myeloma;   Peripheral Neuropathy
    Intervention:  
    Sponsors:   Oncotherapeutics;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified July 2014

  • Conditions:   Multiple Myeloma;   Plasma Cell Myeloma
    Interventions:   Biological: elotuzumab;   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Bristol-Myers Squibb
    Recruiting - verified June 2014

  • Condition:   Myeloproliferative Neoplasms
    Intervention:   Drug: AUY922
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Novartis
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: pomalidomide;   Drug: carfilzomib;   Drug: dexamethasone
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
    Sponsors:   Academic Myeloma Consortium;   Onyx Pharmaceuticals
    Recruiting - verified May 2014

  • Conditions:   GVHD (Acute or Chronic);   Acute Myeloid or Lymphoblastic Leukemia (AML or ALL);   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia (CML);   Multiple Myeloma (MM);   Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell);   Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)
    Intervention:   Drug: milatuzumab
    Sponsors:   Immunomedics, Inc.;   Ohio State University
    Recruiting - verified January 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: ASP7487, Velcade, Dexamethasone
    Sponsors:   University Health Network, Toronto;   Multiple Myeloma Research Consortium;   Astellas Pharma Inc
    Recruiting - verified December 2013

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Busulfan;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Panobinostat, Lenalidomide and Dexamethasone
    Sponsors:   Mount Sinai School of Medicine;   Ajai Chari;   Novartis Pharmaceuticals
    Recruiting - verified December 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatic Complications;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Pancreatic Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Verrucous Carcinoma of the Larynx;   Recurrent Verrucous Carcinoma of the Oral Cavity;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Basal Cell Carcinoma of the Lip;   Stage III Bladder Cancer;   Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage III Lymphoepithelioma of the Nasopharynx;   Stage III Lymphoepithelioma of the Oropharynx;   Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Pancreatic Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Hypopharynx;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage III Verrucous Carcinoma of the Larynx;   Stage III Verrucous Carcinoma of the Oral Cavity;   Stage IIIA Breast Cancer;   Stage IIIA Melanoma;   Stage IIIB Breast Cancer;   Stage IIIB Melanoma;   Stage IIIC Breast Cancer;   Stage IIIC Melanoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Lymphoepithelioma of the Nasopharynx;   Stage IV Melanoma;   Stage IV Pancreatic Cancer;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Basal Cell Carcinoma of the Lip;   Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Lymphoepithelioma of the Oropharynx;   Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVA Squamous Cell Carcinoma of the Larynx;   Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVA Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVA Verrucous Carcinoma of the Larynx;   Stage IVA Verrucous Carcinoma of the Oral Cavity;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Basal Cell Carcinoma of the Lip;   Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Lymphoepithelioma of the Oropharynx;   Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVB Squamous Cell Carcinoma of the Larynx;   Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVB Squamous Cell Carcinoma of the Oropharynx;   Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVB Verrucous Carcinoma of the Larynx;   Stage IVB Verrucous Carcinoma of the Oral Cavity;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVC Basal Cell Carcinoma of the Lip;   Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Lymphoepithelioma of the Oropharynx;   Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IVC Salivary Gland Cancer;   Stage IVC Squamous Cell Carcinoma of the Larynx;   Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IVC Squamous Cell Carcinoma of the Oropharynx;   Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Stage IVC Verrucous Carcinoma of the Larynx;   Stage IVC Verrucous Carcinoma of the Oral Cavity;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
    Interventions:   Drug: romidepsin;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome
    Intervention:   Biological: iTreg
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Hemophilia B
    Intervention:   Biological: AAV8-hFIX19
    Sponsors:   Spark Therapeutics, LLC;   Children's Hospital of Philadelphia;   University of Pittsburgh;   Royal Prince Alfred Hospital, Sydney, Australia;   St. James's Hospital, Ireland
    Recruiting - verified December 2013

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsor:   University of Arkansas
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Daratumumab;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Genmab
    Recruiting - verified February 2014

  • Condition:   Hemophilia A
    Interventions:   Biological: GreenGene™ F and an approved recombinant Factor VIII product;   Biological: GreenGene™ F;   Biological: GreenGene™ F;   Biological: GreenGene™ F
    Sponsors:   Green Cross Corporation;   Atlantic Research Group
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Revlimid
    Sponsor:   University of Arkansas
    Recruiting - verified July 2014

  • Conditions:   Non-Hodgkin's Lymphoma;   Multiple;   Mycosis Fungoides;   Hodgkin's Lymphoma;   Multiple Myeloma
    Intervention:   Drug: Dasatinib
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome;   Lymphoid Leukemia
    Interventions:   Drug: Dasatinib;   Other: laboratory biomarker analysis
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Severe Sepsis;   Coagulopathy
    Interventions:   Drug: ART-123;   Drug: Placebo
    Sponsor:   Asahi Kasei Pharma America Corporation
    Recruiting - verified February 2014

  • Condition:   Von Willebrand Disease
    Intervention:   Other: Patients using wilate as standard of care
    Sponsor:   Octapharma
    Recruiting - verified December 2013

  • Conditions:   Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Biological: Nivolumab;   Biological: Ipilimumab
    Sponsor:   Bristol-Myers Squibb
    Recruiting - verified April 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cytomegalovirus Infection;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Isolated Plasmacytoma of Bone;   Monoclonal Gammopathy of Undetermined Significance;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Biological: tetanus-CMV fusion peptide vaccine;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Congenital Fibrinogen Deficiency;   Afibrinogenemia
    Interventions:   Biological: Octafibrin - (Factor I concentrate);   Biological: Haemocomplettan/Riastap (Factor I concentrate)
    Sponsor:   Octapharma
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: ACY-1215;   Drug: lenalidomide;   Drug: Dexamethasone
    Sponsor:   Acetylon Pharmaceuticals Incorporated
    Recruiting - verified January 2014

  • Conditions:   Multiple Myeloma;   Renal Impairment
    Interventions:   Drug: 4 mg Oral POM + 40 mg Oral DEX;   Drug: 2 mg Oral POM + 40 mg Oral DEX
    Sponsor:   Celgene Corporation
    Recruiting - verified July 2014

  • Condition:   Hemophilia A
    Intervention:  
    Sponsors:   Emory University;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2013

  • Conditions:   Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myeloproliferative Diseases;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
    Interventions:   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting - verified July 2014

  • Condition:   Hemophilia A
    Intervention:   Biological: BAY94-9027
    Sponsor:   Bayer
    Recruiting - verified July 2014

  • Conditions:   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: alisertib;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Relapsed Multiple Myeloma;   Refractory Multiple Myeloma
    Interventions:   Drug: IXAZOMIB + Lenalidomide + Dexamethasone;   Drug: Placebo + Lenalidomide + Dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified June 2014

  • Conditions:   Chronic Lymphocytic Leukemia;   Lymphoma;   Multiple Myeloma
    Intervention:   Drug: Plerixafor
    Sponsor:   Tufts Medical Center
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Dexamethasone
    Sponsors:   Emory University;   Multiple Myeloma Research Consortium;   Novartis;   Onyx Therapeutics, Inc.
    Recruiting - verified February 2014

  • Condition:   Plasma Cell Myeloma
    Interventions:   Drug: Filgrastim;   Drug: Plerixafor;   Procedure: Apheresis
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified October 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Dexamethasone
    Sponsors:   Oncotherapeutics;   Celgene Corporation
    Recruiting - verified June 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Aplastic Anemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Congenital Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Paroxysmal Nocturnal Hemoglobinuria;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Severe Combined Immunodeficiency;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: fludarabine phosphate;   Drug: melphalan;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Drug: methotrexate;   Other: laboratory biomarker analysis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsor:   Roswell Park Cancer Institute
    Recruiting - verified April 2014

  • Conditions:   Hematologic Malignancy;   Leukemia;   Acute Lymphoblastic Leukemia;   ALL;   Acute Myelogenous Leukemia;   AML;   Chronic Lymphocytic Leukemia;   CLL;   Lymphoma;   Hodgkin's Lymphoma;   Non-hodgkin's Lymphoma;   Myeloma
    Interventions:   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil (MMF);   Biological: Hematopoietic Stem Cell Transplant (HSCT)
    Sponsor:   Thomas Jefferson University
    Recruiting - verified February 2014

  • Conditions:   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
    Interventions:   Drug: atorvastatin calcium;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma, Neoplasms
    Interventions:   Drug: cetuximab;   Drug: vemurafenib [Zelboraf];   Drug: vemurafenib [Zelboraf]
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified July 2014

  • Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: dalteparin;   Drug: lenalidomide;   Drug: dexamethasone;   Other: laboratory biomarker analysis
    Sponsors:   University of Southern California;   National Cancer Institute (NCI);   Celgene Corporation
    Recruiting - verified March 2014

  • Conditions:   Myeloproliferative Neoplasms of;   Polycythemia Vera;   Essential Thrombocythemia;   Myelofibrosis
    Intervention:   Drug: LY2784544
    Sponsor:   Eli Lilly and Company
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: TH-302;   Drug: TH-302;   Drug: TH-302 and bortezomib
    Sponsor:   Threshold Pharmaceuticals
    Recruiting - verified April 2014

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Congenital Bleeding Disorder;   Haemophilia A
    Intervention:   Drug: turoctocog alfa
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Vorinostat, Lenalinomide and Dexamethasone
    Sponsors:   Hackensack University Medical Center;   Merck Sharp & Dohme Corp.
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsors:   Celgene Corporation;   Multiple Myeloma Research Consortium
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: carfilzomib and panobinostat
    Sponsors:   SCRI Development Innovations, LLC;   Onyx Therapeutics, Inc.;   Novartis
    Recruiting - verified April 2014

  • Conditions:   Solid Tumors;   Lymphoma;   Multiple Myeloma
    Intervention:   Drug: CS-7017 and Bexarotene
    Sponsors:   Georgetown University;   Daiichi Sankyo Inc.
    Recruiting - verified February 2014

  • Conditions:   Congenital Bleeding Disorder;   Haemophilia A
    Intervention:   Drug: NNC 0129-0000-1003
    Sponsor:   Novo Nordisk A/S
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Ganetespib;   Drug: Bortezomib;   Drug: Dexamethasone
    Sponsors:   Emory University;   Multiple Myeloma Research Consortium
    Recruiting - verified March 2014

  • Condition:   High-risk Smoldering Multiple Myeloma
    Interventions:   Drug: Siltuximab;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting - verified July 2014

  • Condition:   Hemophilia A
    Intervention:   Biological: Recombinant Factor VIII (rFVIII)
    Sponsor:   CSL Behring
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: PCI-32765;   Drug: Dexamethasone
    Sponsors:   Pharmacyclics;   Janssen Research & Development, LLC
    Recruiting - verified July 2014

  • Conditions:   Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Marginal Zone Lymphoma;   Follicular Lymphomas;   Large-cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   High Grade Lymphomas;   Mantle-cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Intervention:   Biological: HSC835
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Simvastatin and zoledronic acid
    Sponsors:   James Graham Brown Cancer Center;   University of Louisville
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Elotuzumab;   Drug: Bortezomib;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified October 2013

  • Condition:   Multiple Myeloma
    Intervention:   Drug: lenalidomide
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Montefiore Medical Center;   State University of New York - Downstate Medical Center;   University of Rochester;   Weill Medical College of Cornell University;   Stamford Hospital
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
    Sponsors:   Academic Myeloma Consortium;   Criterium Inc.;   Onyx Pharmaceuticals;   Celgene Corporation
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Fludarabine monophosphate, melphalan, Bortezomib
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: LGH447;   Drug: midazolam
    Sponsors:   Novartis;   Novartis Pharmaceuticals
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsors:   Multiple Myeloma Research Foundation;   Translational Genomics Research Institute, Phoenix, Arizona.;   Spectrum Health Hospitals;   Van Andel Research Institute
    Recruiting - verified June 2014

  • Conditions:   Idiopathic Thrombocytopenic Purpura;   Thrombocytopenia;   Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP);   Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP);   Thrombocytopenic Purpura;   Immune Thrombocytopenia
    Interventions:   Drug: romiplostim;   Drug: Placebo
    Sponsor:   Amgen
    Recruiting - verified June 2014

  • Condition:   Smoldering Multiple Myeloma
    Intervention:   Biological: Elotuzumab (BMS-901608; HuLuc63)
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified June 2014

  • Condition:   Myeloma
    Interventions:   Drug: Panobinostat;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Behavioral: Symptom Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   Novartis
    Recruiting - verified May 2014

  • Condition:   Blood Coagulation Disorders
    Intervention:   Device: method of returning residual CPB blood ( Hemobag®)
    Sponsors:   Maine Medical Center;   Global Blood Resources, LLC
    Recruiting - verified April 2014

  • Condition:   Hemophilia B
    Intervention:   Drug: rFIXFc
    Sponsors:   Biogen Idec;   Swedish Orphan Biovitrum
    Recruiting - verified April 2012

  • Conditions:   Multiple Myeloma;   Multiple Myeloma in Relapse;   Mantle Cell Lymphoma in Relapse;   Diffuse Large B Cell Lymphoma in Relapse;   Other B Cell Lymphoma in Relapse;   Plasma Cell Leukemia
    Interventions:   Biological: SNS01-T;   Biological: SNS01-T;   Biological: SNS01-T;   Biological: SNS01-T
    Sponsor:   Senesco Technologies, Inc.
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Intervention:   Biological: CD3/CD28
    Sponsor:   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified August 2013

  • Condition:   Hemophilia A
    Interventions:   Biological: PF-05280602;   Biological: PF-05280602;   Biological: PF-05280602;   Biological: PF-05280602
    Sponsor:   Pfizer
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Intervention:   Procedure: Blood draws
    Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center
    Recruiting - verified April 2014

  • Conditions:   Solid Tumors;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Glioblastoma Multiforme;   Oligodendroglioma;   Hepatocellular Carcinoma;   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
    Intervention:   Drug: CC-122 HCL
    Sponsor:   Celgene Corporation
    Recruiting - verified April 2014

  • Conditions:   Primary Myelofibrosis;   Post-Polycythemic Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
    Intervention:   Drug: NS-018
    Sponsor:   NS Pharma, Inc.
    Recruiting - verified February 2014

  • Conditions:   Myelofibrosis;   Gaucher Disease;   Pulmonary Fibrosis;   Hermansky-Pudlak Syndrome (HPS);   Cancer
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
    Recruiting - verified February 2014

  • Condition:   Coagulation Defects
    Interventions:   Biological: Spray-dried S/D-treated Plasma;   Drug: Spray-dried S/D-treated plasma;   Biological: Spray-dried S/D-treated Plasma;   Biological: Spray-dried S/D-treated Plasma
    Sponsor:   Entegrion, Inc.
    Recruiting - verified November 2013

  • Conditions:   Multiple Myeloma;   Waldenstrom Macroglobulinemia
    Intervention:   Drug: oprozomib
    Sponsors:   Onyx Pharmaceuticals;   Onyx Therapeutics, Inc.
    Recruiting - verified June 2014

  • Condition:   Myeloma
    Interventions:   Drug: G-CSF;   Drug: Plerixafor;   Procedure: Apheresis;   Drug: Melphalan;   Procedure: Stem cell re-infusion;   Drug: Basiliximab;   Device: CliniMACS CD25 microbeads and cell sorter
    Sponsor:   University of Chicago
    Recruiting - verified March 2014

  • Condition:   Wiskott-Aldrich Syndrome
    Intervention:   Biological: Retrovirus-mediated gene transfer
    Sponsor:   Children's Hospital Boston
    Recruiting - verified January 2014

  • Conditions:   Acute Myelogenous Leukemia (AML) in 1st or Subsequent Remission;   Acute Lymphoblastic Leukemia (ALL) in 1st or Subsequent Remission;   Chronic Myelogenous Leukemia (CML);   Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or Greater Complete Remission, Partial Remission;   Chronic Lymphocytic Leukemia (CLL);   Multiple Myeloma (MM);   Myelodysplastic Syndrome (MDS);   Myeloproliferative Disorder (MPD)
    Interventions:   Drug: POL6326;   Procedure: Leukapheresis;   Procedure: PBSC Transplant
    Sponsor:   Polyphor Ltd.
    Recruiting - verified February 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: ixazomib;   Drug: dexamethasone
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Conditions:   Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
    Intervention:   Procedure: tissue banking
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting - verified April 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: plerixafor;   Biological: filgrastim;   Drug: etoposide;   Procedure: leukapheresis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Acute Coagulopathy
    Interventions:   Biological: Blood product transfusion based on conventional coagulation tests.;   Biological: Blood product transfusion based on rapid thrombelastography (r-TEG) results.
    Sponsors:   Denver Health and Hospital Authority;   Haemonetics Corporation
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Drug: Lenalidomide;   Drug: Lenalidomide
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified May 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Thomas Jefferson University
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Melphalan;   Drug: Bortezomib
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified February 2014

  • Conditions:   Light Chain Deposition Disease (LCDD or MIDD);   Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);   Monoclonal Immunoglobulin Deposition Disease (MIDD);   Amyloidosis
    Intervention:   Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified February 2014

  • Conditions:   Cognitive/Functional Effects;   Fatigue;   Neurotoxicity;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-related Toxicity;   Waldenström Macroglobulinemia
    Interventions:   Drug: temsirolimus;   Biological: rituximab;   Drug: bortezomib;   Drug: dexamethasone;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Relapsed Multiple Myeloma
    Interventions:   Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
    Sponsors:   Boston VA Research Institute, Inc.;   Celgene Corporation;   Kansas City Veteran Affairs Medical Center;   VA Pittsburgh Healthcare System;   VA Greater Los Angeles Healthcare System;   Michael Debakey Veterans Affairs Medical Center;   Edward Hines Jr. VA Hospital
    Recruiting - verified October 2013

  • Conditions:   Neutropenia;   Sickle Cell Disease;   Decitabine;   Fetal Hemoglobin
    Intervention:   Drug: Decitabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified November 2013

  • Condition:   Myeloma
    Interventions:   Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim
    Sponsors:   M.D. Anderson Cancer Center;   Array BioPharma;   Onyx Therapeutics, Inc.
    Recruiting - verified April 2014

  • Condition:   Hemophilia A
    Intervention:   Drug: FVIII concentrate
    Sponsors:   The University of Texas Health Science Center, Houston;   Rho;   Baxter Healthcare Corporation
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Amrubicin;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin
    Sponsors:   Stanford University;   Michaela Liedtke;   Celgene Corporation
    Recruiting - verified September 2013

  • Conditions:   B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
    Intervention:   Drug: AVL-292
    Sponsors:   Celgene Corporation;   The Leukemia and Lymphoma Society
    Recruiting - verified February 2014

  • Conditions:   Primary Myelofibrosis;   Post Essential Thrombocythemia-myelofibrosis;   Post Polycythemia Vera-myelofibrosis
    Intervention:   Drug: Ruxolitinib (INCB018424)
    Sponsor:   Incyte Corporation
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine;   Biological: Prevnar-13
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Celgene Corporation
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Intervention:   Genetic: Autologous Genetically modified T cells
    Sponsors:   Adaptimmune;   University of Maryland Greenebaum Cancer Center;   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified December 2013

  • Conditions:   Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
    Interventions:   Drug: Denosumab;   Drug: Zoledronic acid
    Sponsors:   Amgen;   Daiichi Sankyo Inc.
    Recruiting - verified July 2014

  • Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
    Intervention:   Procedure: Bone Marrow Transplant
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified March 2014

  • Conditions:   Non-Hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Plerixafor;   Drug: Filgrastim
    Sponsor:   University of Florida
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Biological: Elotuzumab (BMS-901608; HuLuc63)
    Sponsors:   Bristol-Myers Squibb;   AbbVie
    Recruiting - verified January 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: IXAZOMIB;   Drug: Melphalan 9 mg/m2;   Drug: Melphalan 6 mg/m2;   Drug: Prednisone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2014

  • Conditions:   Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
    Intervention:   Procedure: Allogeneic transplantation
    Sponsor:   Scripps Health
    Recruiting - verified December 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
    Interventions:   Drug: veliparib;   Drug: bendamustine hydrochloride;   Biological: rituximab;   Other: pharmacological study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Myelofibrosis
    Intervention:   Drug: Ruxolitinib
    Sponsors:   Incyte Corporation;   Novartis
    Recruiting - verified April 2014

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
    Interventions:   Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Minnesota Medical Foundation
    Recruiting - verified May 2014

  • Condition:   Haemophilia A
    Intervention:   Biological: Recombinant Factor VIII (BAY81-8973)
    Sponsor:   Bayer
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Lenalidomide
    Sponsors:   Indiana University;   Indiana University School of Medicine;   Celgene Corporation
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified February 2014

  • Conditions:   Patients Undergoing Routine Health Care;   Heart Diseases;   Inflammatory Bowel Diseases;   Autoimmune Disease;   Inflammatory Disease;   Blood Coagulation Disorders;   Hepatitis C;   Non-Metastatic Neoplasm
    Intervention:  
    Sponsor:   University of Chicago
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Intervention:   Drug: Eltrombopag
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified September 2013

  • Conditions:   Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma;   Multiple Myeloma;   Waldenstrom Macroglobulinemia;   Breast Cancer;   Renal Cell Carcinoma;   Melanoma;   Sarcoma;   Ovarian Cancer;   Thymoma
    Interventions:   Procedure: Nonmyeloablative Allogeneic Transplant;   Procedure: Nonmyeloablative Allogeneic Transplant
    Sponsor:   Scripps Health
    Recruiting - verified December 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: panobinostat;   Other: laboratory biomarker analysis;   Genetic: western blotting;   Genetic: DNA analysis;   Other: flow cytometry;   Other: pharmacological study;   Other: immunohistochemistry staining method
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
    Interventions:   Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
    Sponsors:   Mount Sinai School of Medicine;   Ronald Hoffman;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG;   QIAGEN Marseille
    Recruiting - verified June 2014

  • Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
    Interventions:   Drug: PEGASYS;   Drug: Aspirin
    Sponsors:   Mount Sinai School of Medicine;   Ronald Hoffman;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG;   QIAGEN Marseille
    Recruiting - verified June 2014

  • Conditions:   Thrombotic Thrombocytopenic Purpura;   Congenital Thrombotic Thrombocytopenic Purpura;   Familial Thrombotic Thrombocytopenic Purpura;   Thrombotic Thrombocytopenic Purpura, Congenital;   Upshaw-Schulman Syndrome
    Intervention:   Other: Observation
    Sponsors:   University Hospital Inselspital, Berne;   Swiss National Science Foundation;   Mach-Gaensslen Foundation Switzerland;   Baxter Healthcare Corporation
    Recruiting - verified June 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: sirolimus;   Drug: cyclosporine;   Drug: mycophenolate mofetil
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma, Plasma Cell Leukemia
    Interventions:   Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous;   Drug: Dexamethasone, steroid; oral;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;   Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous;   Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous;   Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
    Sponsor:   Array BioPharma
    Recruiting - verified April 2014

  • Conditions:   Multiple Myeloma;   Auto Stem Cell Transplant
    Intervention:   Drug: Bortezomib
    Sponsor:   Hackensack University Medical Center
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: carfilzomib;   Drug: pegylated liposomal doxorubicin (PLD);   Drug: Dexamethasone
    Sponsor:   Washington University School of Medicine
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Adoptive Immunotherapy;   Drug: Th1/Tc1 product
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   Hackensack University Medical Center
    Recruiting - verified March 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: sirolimus;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Adult Diffuse Mixed Cell Lymphoma;   Adult Diffuse Small Cleaved Cell Lymphoma;   Adult Grade III Lymphomatoid Granulomatosis;   Adult Immunoblastic Large Cell Lymphoma;   Adult Lymphoblastic Lymphoma;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia With Nodal Disease
    Interventions:   Biological: dendritic cell vaccine therapy;   Procedure: cryotherapy;   Biological: pneumococcal polyvalent vaccine;   Other: laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Biological: autologous dendritic cell-tumor fusion vaccine
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: VELCADE;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: DVT prophylaxis;   Drug: Bisphosphonates;   Drug: Liposomal doxorubicin;   Drug: Dexamethasone
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting - verified April 2014

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: gene expression analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia (CML);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic Syndrome (MDS);   Myeloproliferative Neoplasms (MPN);   Myelodysplastic/Myeloproliferative Neoplasm Overlap;   Multiple Myeloma (MM);   Myelofibrosis (MF)
    Intervention:   Drug: KB004, Monoclonal Antibody
    Sponsor:   KaloBios Pharmaceuticals
    Recruiting - verified June 2014

  • Condition:   Lymphoma
    Intervention:   Biological: DNA Vaccine
    Sponsor:   M.D. Anderson Cancer Center
    Not yet recruiting - verified May 2014

  • Conditions:   AML;   ALL;   Blast Crisis;   MDS;   Multiple Myeloma
    Interventions:   Drug: TG02 citrate;   Drug: Carfilzomib
    Sponsor:   Tragara Pharmaceuticals, Inc.
    Recruiting - verified January 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bendamustine;   Drug: Doxorubicin;   Drug: Bortezomib;   Drug: Bendamustine;   Drug: Filgrastim
    Sponsors:   Hoosier Cancer Research Network;   Cephalon
    Recruiting - verified February 2014

  • Conditions:   Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
    Intervention:  
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma
    Intervention:   Radiation: Total Skeletal Irradiation
    Sponsor:   University of Rochester
    Recruiting - verified October 2013

  • Conditions:   Light Chain Deposition Disease;   Smoldering Multiple Myeloma
    Interventions:   Drug: lenalidomide;   Other: clinical observation;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma
    Interventions:   Drug: bortezomib;   Drug: fludarabine phosphate;   Other: melphalan;   Radiation: total marrow irradiation;   Drug: tacrolimus;   Drug: sirolimus;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Hereditary Hemorrhagic Telangiectasia
    Intervention:  
    Sponsors:   St. Michael's Hospital, Toronto;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting - verified November 2013

  • Condition:   Refractory Multiple Myeloma
    Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: dexamethasone;   Other: DNA methylation analysis;   Other: gene expression analysis;   Other: bone marrow aspiration;   Other: immunohistochemistry staining method;   Other: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified September 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Lenalidomide plus Melphalan during autologous stem cell transplantation;   Drug: Lenalidomide maintenance
    Sponsors:   Indiana University;   Indiana University School of Medicine;   Celgene Corporation
    Recruiting - verified May 2014

  • Conditions:   Multiple Myeloma;   Leukemia;   MGUS;   MBL
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified September 2013

  • Conditions:   Chronic Myeloproliferative Disorders;   Cognitive/Functional Effects;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:  
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm
    Interventions:   Other: biologic sample preservation procedure;   Other: cytology specimen collection procedure
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: busulfan, melphalan and fludarabine;   Drug: busulfan, melphalan and fludarabine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Otsuka America Pharmaceutical;   Ludwig Institute for Cancer Research
    Recruiting - verified June 2014

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system
    Sponsor:   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: velcade;   Drug: Pralatrexate
    Sponsors:   Stanford University;   Michaela Liedtke;   National Comprehensive Cancer Network
    Recruiting - verified November 2013

  • Condition:   Relapsed/Refractory Multiple Myeloma
    Interventions:   Drug: plitidepsin + dexamethasone;   Drug: dexamethasone
    Sponsor:   PharmaMar
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:  
    Sponsor:   Celgene Corporation
    Recruiting - verified December 2013

  • Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: temsirolimus;   Other: laboratory biomarker analysis
    Sponsor:   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Purpura, Thrombocytopaenic, Idiopathic
    Intervention:   Drug: Eltrombopag
    Sponsor:   GlaxoSmithKline
    Recruiting - verified September 2013

  • Condition:   Multiple Myeloma
    Interventions:   Drug: azacitidine;   Drug: lenalidomide
    Sponsors:   Virginia Commonwealth University;   National Cancer Institute (NCI);   Celgene Corporation
    Recruiting - verified March 2014

  • Condition:   Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
    Intervention:   Biological: Romiplostim
    Sponsor:   Amgen
    Recruiting - verified July 2014

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Biological: rituximab;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan
    Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified November 2013

  • Conditions:   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: filgrastim;   Procedure: peripheral blood stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation;   Procedure: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Chronic Lymphocytic Leukemia;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: laboratory biomarker analysis;   Procedure: peripheral blood stem cell transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Hemophilia B
    Intervention:   Genetic: Gene Transfer
    Sponsors:   St. Jude Children's Research Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Hemophilia of Georgia, Inc.;   Children's Hospital of Philadelphia;   University of Kentucky;   The Hemophilia Center of Western Pennsylvania;   Oregon Health and Science University;   University of Texas;   Scott and White Hospital & Clinic
    Recruiting - verified June 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Procedure: leukapheresis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Institute of Allergy and Infectious Diseases (NIAID);   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Thrombotic Thrombocytopenic Purpura
    Intervention:   Drug: Danazol
    Sponsors:   Beth Israel Medical Center;   St. Luke's - Roosevelt Hoapital Center
    Recruiting - verified March 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
    Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Rambam Health Care Campus;   Gateway for Cancer Research;   Department of Defense
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Bortezomib;   Drug: Melphalan;   Procedure: Autologous Stem Cell Transplant;   Drug: Bortezomib;   Drug: Fludarabine;   Drug: Melphalan
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified June 2014

  • Conditions:   Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma;   Lymphoma
    Interventions:   Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG);   Procedure: Stem Cell Transplant;   Procedure: Stem Cells Collections;   Drug: Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI);   Drug: Fludarabine, Busulfan, and ATG
    Sponsor:   University of Chicago
    Recruiting - verified March 2014

  • Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
    Intervention:   Device: 3'-deoxy-3'-[18F]fluorothymidine
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified August 2013

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: panobinostat;   Drug: everolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Plerixafor (AMD3100);   Drug: bortezomib
    Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Genzyme, a Sanofi Company;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2014

  • Condition:   Lymphoma
    Intervention:   Procedure: leukapheresis
    Sponsors:   National Cancer Institute (NCI);   Herbert Irving Comprehensive Cancer Center
    Recruiting - verified January 2008

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Intervention:   Biological: human myeloid progenitor cells
    Sponsors:   Cellerant Therapeutics;   Department of Health and Human Services
    Recruiting - verified November 2013

  • Conditions:   Lymphoma;   Myeloma;   Leukemia
    Intervention:   Biological: Kappa CD28 T cells
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified April 2014

  • Condition:   Myeloma
    Intervention:   Drug: Velcade, Revlimid, Dexamethasone, Melphalan, Cisplatin, Thalidomide
    Sponsor:   University of Arkansas
    Recruiting - verified June 2014

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Multiple Myeloma;   End Stage Renal Disease
    Interventions:   Drug: Cyclophosphamide, anti-thymocyte globulin;   Procedure: Kidney transplant;   Radiation: Thymic irradiation;   Procedure: Bone marrow transplant from a related donor
    Sponsor:   Massachusetts General Hospital
    Recruiting - verified March 2014

  • Conditions:   Menkes Disease;   Occipital Horn Syndrome;   Unexplained Copper Deficiency
    Intervention:   Drug: Copper Histidine
    Sponsors:   National Institutes of Health Clinical Center (CC);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting - verified July 2013

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem cell transplant x 1 or x 2;   Drug: lenalidomide and dexamethasone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Tufts Medical Center;   Lahey Clinic
    Recruiting - verified June 2014

  • Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Drug: bortezomib;   Drug: cyclosporine;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: melphalan;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2014

  • Conditions:   Multiple Myeloma;   Plasma Cell Neoplasm
    Interventions:   Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
    Sponsors:   PrECOG, LLC.;   Celgene Corporation
    Recruiting - verified July 2014

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Biological: natural killer cell therapy
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   Wayne D. Kuni and Joan E. Kuni Foundation
    Recruiting - verified May 2014

  • Conditions:   Wiskott-Aldrich Syndrome (WAS);   X-linked Thrombocytopenia
    Intervention:   Drug: Interleukin-2
    Sponsors:   Children's Hospital of Philadelphia;   Soma Jyonouchi
    Recruiting - verified June 2014

  • Conditions:   Cardiovascular Disease;   HIV Infections
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified February 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Anaplastic Large Cell Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: double-unit umbilical cord blood transplantation;   Procedure: umbilical cord blood transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Condition:   Thrombotic Thrombocytopenic Purpura
    Interventions:   Drug: Cyclosporine;   Drug: Prednisone
    Sponsor:   Ohio State University
    Recruiting - verified March 2014

  • Conditions:   Lymphoma, Non-Hodgkin;   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell;   Monoclonal B-Cell Lymphocytosis;   Multiple Myeloma
    Intervention:  
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified June 2014

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2014

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: umbilical cord blood transplantation;   Drug: Allopurinol;   Drug: fludarabine phosphate;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Treg infusion;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Multifocal Lymphangioendotheliomatosis With Thrombocytopenia;   Cutaneovisceral Angiomatosis With Thrombocytopenia;   Vascular Anomaly With Thrombocytopenia;   Hemangiomas
    Intervention:   Other: no intervention
    Sponsor:   Medical College of Wisconsin
    Recruiting - verified September 2013

  • Conditions:   Lymphoma;   Leukemia;   Multiple Myeloma;   Colon Cancer;   Renal Cancer
    Intervention:  
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Montefiore Medical Center;   Children's Hospital of Philadelphia
    Recruiting - verified July 2014

  • Condition:   Multiple Myeloma
    Intervention:   Other: No drugs are involved
    Sponsor:   University of Arkansas
    Recruiting - verified February 2014

  • Condition:   Respiratory Distress Syndrome, Adult
    Intervention:  
    Sponsors:   University of California, San Francisco;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2014

  • Condition:   Von Willebrand Disease
    Intervention:   Biological: Alphanate SD/HT
    Sponsor:   Grifols Biologicals Inc.
    Recruiting - verified February 2014

  • Condition:   Hemophilia A
    Interventions:   Biological: Moroctocog alfa (AF-CC);   Biological: Moroctocog alfa (AF-CC)
    Sponsor:   Pfizer
    Recruiting - verified June 2014

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Biological: rituximab;   Drug: Methotrexate;   Drug: Sirolimus;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine sulfate;   Drug: Cytarabine;   Drug: Tacrolimus;   Biological: Alemtuzumab
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2014

  • Condition:   Idiopathic Thrombocytopenic Purpura
    Intervention:   Biological: IGIV3I Grifols 10%
    Sponsor:   Grifols Biologicals Inc.
    Recruiting - verified September 2013

  • Condition:   Multiple Myeloma
    Intervention:   Drug: NPI-0052
    Sponsor:   Triphase Research and Development I Corporation
    Recruiting - verified April 2014

  • Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Biological: MV-NIS;   Drug: cyclophosphamide;   Other: I-123 prior MV-NIS;   Other: I-123 post MV-NIS;   Drug: Liothyronine
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis
    Interventions:   Drug: Busulfan;   Drug: Cytarabine;   Drug: Fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Paroxysmal Nocturnal Hemoglobinuria;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Polycythemia Vera;   Primary Myelofibrosis;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis
    Interventions:   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Autoimmune Pancytopenia;   Autoimmune Lymphoproliferative Syndrome (ALPS);   Evans Syndrome;   Idiopathic Thrombocytopenic Purpura;   Anemia, Hemolytic, Autoimmune;   Autoimmune Neutropenia;   Lupus Erythematosus, Systemic;   Inflammatory Bowel Disease;   Rheumatoid Arthritis
    Intervention:   Drug: sirolimus
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting - verified February 2014

  • Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: bortezomib;   Drug: dexamethasone
    Sponsors:   National Cancer Institute (NCI);   Sparrow Regional Cancer Center
    Recruiting - verified June 2009

  • Conditions:   Lymphoma;   Leukemia;   Multiple Myeloma;   Lymphoid Malignancies
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   Lymphoma/Leukemia Molecular Profiling Project (LLMPP)
    Recruiting - verified December 2013

  • Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: bortezomib;   Drug: melphalan;   Drug: pegylated liposomal doxorubicin hydrochloride
    Sponsors:   National Cancer Institute (NCI);   Herbert Irving Comprehensive Cancer Center
    Recruiting - verified August 2008

  • Condition:   Severe Hemophilia A
    Intervention:   Drug: Alphanate SD/HT
    Sponsor:   Grifols Biologicals Inc.
    Recruiting - verified February 2014

  • Condition:   Antithrombin III Deficiency
    Intervention:   Drug: Plasma-derived AT-III concentrate
    Sponsor:   Grifols Biologicals Inc.
    Recruiting - verified February 2014

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma;   Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total body irradiation;   Drug: filgrastim
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified July 2014

  • Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Interventions:   Biological: graft-versus-tumor induction therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: radiation therapy
    Sponsor:   University of Rochester
    Recruiting - verified October 2013

  • Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition
    Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total Body Irradiation (TBI);   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Phenytoin;   Drug: Methotrexate
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified July 2014

  • Condition:   Glanzmann Thrombasthenia
    Intervention:  
    Sponsor:   Rockefeller University
    Recruiting - verified May 2014

  • Conditions:   Hereditary Bleeding Disorder;   Thrombotic Disorder
    Intervention:  
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting - verified May 2014

  • Condition:   Hemophilia A
    Intervention:  
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting - verified May 2014

  • Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Leukemia, Myeloid, Chronic;   Lymphomas;   Multiple Myeloma;   Myelodysplastic Syndrome;   Leukemia, Lymphocytic, Acute;   Leukemia, Lymphocytic, Chronic;   AML
    Interventions:   Procedure: Donor Lymphocyte Infusion;   Drug: Induction Chemotherapy + DLI
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aggressive NK-cell Leukemia;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid/NK-cell Acute Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: pentostatin;   Biological: therapeutic allogeneic lymphocytes;   Drug: mycophenolate mofetil;   Drug: cyclosporine
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2014

  • Conditions:   Waldenstrom Macroglobulinemia;   Chronic Lymphocytic Leukemia;   Hodgkin Disease;   NonHodgkin Lymphoma;   Mixed Lymphoproliferative Disease
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified May 2014

  • Conditions:   Chronic Myeloproliferative Disorders;   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Neuroblastoma;   Oral Complications;   Ovarian Cancer;   Pain;   Sarcoma
    Interventions:   Procedure: management of therapy complications;   Procedure: pain therapy
    Sponsors:   National Cancer Institute (NCI);   Medical College of Wisconsin
    Recruiting - verified June 2009

  • Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: therapeutic autologous lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified March 2014

  • Conditions:   Albinism;   Intestinal Disease;   Kidney Disease;   Myocardial Disease;   Pulmonary Fibrosis
    Intervention:  
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
    Recruiting - verified May 2014

  • Conditions:   Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
    Intervention:   Procedure: Stem cell transplantation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified September 2013


PaidClinicalTrials.orgPaidClinicalTrials.org